biostudies-literatureHosoya HNCATS NIH HHSNational Institutes of Health183-191https://www.ebi.ac.uk/biostudies/studies/S-EPMC8715952biostudies-literatureUnknown16(2)<h4>Purpose of review</h4>The field of multiple myeloma treatment has entered a new era with antibody-based approaches in clinical practice. In this review, we focus on the clinical approaches of utilizing antibody-based modality, specifically monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell antibodies in the treatment of multiple myeloma.<h4>Recent findings</h4>Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment of multiple myeloma. There are many ongoing clinical trials using novel targets and constructs, including bispecific antibodies against BCMA, GPRC5D, and FCRH5. In addition to exploring Current hematologic malignancy reportsAntibody-Based Treatment Approaches in Multiple Myeloma.PMC8715952KL2 TR003143KL2TR003143, KL2 Mentored Career Development Program, Stanford Clinical Translational Science Award ProgramSidana SHosoya HfalseAntibody-Based Treatment Approaches in Multiple Myeloma.<h4>Purpose of review</h4>The field of multiple myeloma treatment has entered a new era with antibody-based approaches in clinical practice. In this review, we focus on the clinical approaches of utilizing antibody-based modality, specifically monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell antibodies in the treatment of multiple myeloma.<h4>Recent findings</h4>Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment of multiple myeloma. There are many ongoing clinical trials using novel targets and constructs, including bispecific antibodies against BCMA, GPRC5D, and FCRH5. In addition to exploring 2021-01-01T00:00:00Z2021 Apr2025-04-04T23:02:46.202Z2025-04-04T23:02:46.202ZS-EPMC87159523373036010.1007/s11899-021-00624-6